{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:42:55Z","timestamp":1792212175289,"version":"4.4.0"},"reference-count":56,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,10,16]]},"DOI":"10.1248\/bpb.b26-00395","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:11:57Z","timestamp":1792102317000},"page":"1676-1685","source":"Crossref","is-referenced-by-count":0,"title":["Association between Low Plasma Phylloquinone Concentration and Warfarin Sensitivity in Japanese Patients"],"prefix":"10.1248","volume":"49","author":[{"given":"Ayumu","family":"Nagamine","sequence":"first","affiliation":[{"name":"Education Center for Clinical Pharmacy, Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki, Gunma 370\u20130033, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Nishiba","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacy, Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki, Gunma 370\u20130033, Japan"},{"name":"Division of Pharmacy, Japan Community Health Care Organization (JCHO) Gunma Chuo Hospital, 1\u20137\u201313 Koun-cho, Maebashi, Gunma 371\u20130025, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Education Center for Clinical Pharmacy, Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki, Gunma 370\u20130033, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Yashima","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, 3\u201339\u201322 Showa-machi, Maebashi, Gunma 371\u20138511, Japan"},{"name":"Department of Pharmacy, Gunma University Hospital, 3\u201339\u201315 Showa-machi, Maebashi, Gunma 371\u20138511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gunma University Hospital, 3\u201339\u201315 Showa-machi, Maebashi, Gunma 371\u20138511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Nutrition, Faculty of Health and Welfare, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki, Gunma 370\u20130033, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Takama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, 3\u201339\u201322 Showa-machi, Maebashi, Gunma 371\u20138511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimichi","family":"Koitabashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, 3\u201339\u201322 Showa-machi, Maebashi, Gunma 371\u20138511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, 3\u201339\u201322 Showa-machi, Maebashi, Gunma 371\u20138511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ohyama","sequence":"additional","affiliation":[{"name":"Innovative Medical Research Center, Gunma University Hospital, 3\u201339\u201315 Showa-machi, Maebashi, Gunma 371\u20138511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3\u201339\u201322 Showa-machi, Maebashi, Gunma 371\u20138514, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Imai","sequence":"additional","affiliation":[{"name":"Health Care Center, Japan Community Health Care Organization (JCHO) Gunma Chuo Hospital, 1\u20137\u201313 Koun-cho, Maebashi, Gunma 371\u20130025, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Department of Nutrition, Faculty of Health and Welfare, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki, Gunma 370\u20130033, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kurabayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, 3\u201339\u201322 Showa-machi, Maebashi, Gunma 371\u20138511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koujirou","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, 3\u201339\u201322 Showa-machi, Maebashi, Gunma 371\u20138511, Japan"},{"name":"Department of Pharmacy, Gunma University Hospital, 3\u201339\u201315 Showa-machi, Maebashi, Gunma 371\u20138511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, 3\u201339\u201322 Showa-machi, Maebashi, Gunma 371\u20138511, Japan"},{"name":"Department of Pharmacy, Gunma University Hospital, 3\u201339\u201315 Showa-machi, Maebashi, Gunma 371\u20138511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Obayashi","sequence":"additional","affiliation":[{"name":"Education Center for Clinical Pharmacy, Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki, Gunma 370\u20130033, Japan"},{"name":"Laboratory of Clinical Pharmacy, Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki, Gunma 370\u20130033, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MTM, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. <i>N. Engl. J. Med.<\/i>, <b>360<\/b>, 753\u2013764 (2009).","DOI":"10.1056\/NEJMoa0809329"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, Larue S, Langlois N, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Carrier M, Forgie M, Wells PS, Kim RB. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. <i>Blood<\/i>, <b>118<\/b>, 3163\u20133171 (2011).","DOI":"10.1182\/blood-2011-03-345173"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Limdi NA, Brown TM, Yan Q, Thigpen JL, Shendre A, Liu N, Hill CE, Arnett DK, Beasley TM. Race influences warfarin dose changes associated with genetic factors. <i>Blood<\/i>, <b>126<\/b>, 539\u2013545 (2015).","DOI":"10.1182\/blood-2015-02-627042"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of \u03b3-carboxyglutamic acid. <i>Blood<\/i>, <b>93<\/b>, 1798\u20131808 (1999).","DOI":"10.1182\/blood.V93.6.1798.406k22_1798_1808"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Merli GJ, Fink J. Vitamin K and thrombosis. <i>Vitam. Horm.<\/i>, <b>78<\/b>, 265\u2013279 (2008).","DOI":"10.1016\/S0083-6729(07)00013-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Beulens JWJ, Booth SL, van den Heuvel EGHM, Stoecklin E, Baka A, Vermeer C. The role of menaquinones (vitamin K<sub>2<\/sub>) in human health. <i>Br. J. Nutr.<\/i>, <b>110<\/b>, 1357\u20131368 (2013).","DOI":"10.1017\/S0007114513001013"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Tie JK, Stafford DW. Structural and functional insights into enzymes of the vitamin K cycle. <i>J. Thromb. Haemost.<\/i>, <b>14<\/b>, 236\u2013247 (2016).","DOI":"10.1111\/jth.13217"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. <i>Trends Pharmacol. Sci.<\/i>, <b>30<\/b>, 375\u2013386 (2009).","DOI":"10.1016\/j.tips.2009.05.001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kim S-Y, Kang J-Y, Hartman JH, Park S-H, Jones DR, Yun C-H, Boysen G, Miller GP. Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. <i>Drug Metab. Lett.<\/i>, <b>6<\/b>, 157\u2013164 (2012).","DOI":"10.2174\/1872312811206030002"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. <i>Mol. Pharmacol.<\/i>, <b>75<\/b>, 1337\u20131346 (2009).","DOI":"10.1124\/mol.109.054833"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Edson KZ, Prasad B, Unadkat JD, Suhara Y, Okano T, Guengerich FP, Rettie AE. Cytochrome P450-dependent catabolism of vitamin K: <i>\u03c9<\/i>-hydroxylation catalyzed by human CYP4F2 and CYP4F11. <i>Biochemistry<\/i>, <b>52<\/b>, 8276\u20138285 (2013).","DOI":"10.1021\/bi401208m"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yuan HY, Chen JJ, Lee MTM, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. <i>Hum. Mol. Genet.<\/i>, <b>14<\/b>, 1745\u20131751 (2005).","DOI":"10.1093\/hmg\/ddi180"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Hamberg AK, Dahl ML, Barban M, Scordo MG, Wadelius M, Pengo V, Padrini R, Jonsson EN. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. <i>Clin. Pharmacol. Ther.<\/i>, <b>81<\/b>, 529\u2013538 (2007).","DOI":"10.1038\/sj.clpt.6100084"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sad\u00e9e W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. <i>Blood<\/i>, <b>112<\/b>, 1013\u20131021 (2008).","DOI":"10.1182\/blood-2008-03-144899"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Sangviroon A, Panomvana D, Tassaneeyakul W, Namchaisiri J. Pharmacokinetic and pharmacodynamic variation associated with <i>VKORC1<\/i> and <i>CYP2C9<\/i> polymorphisms in Thai patients taking warfarin. <i>Drug Metab. Pharmacokinet.<\/i>, <b>25<\/b>, 531\u2013538 (2010).","DOI":"10.2133\/dmpk.DMPK-10-RG-059"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Wolkanin-Bartnik J, Pogorzelska H, Szperl M, Bartnik A, Koziarek J, Bilinska ZT. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm. <i>Pharmacogenet. Genomics<\/i>, <b>23<\/b>, 611\u2013618 (2013).","DOI":"10.1097\/FPC.0000000000000004"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Hirai K, Hayashi H, Ono Y, Izumiya K, Tanaka M, Suzuki T, Sakamoto T, Itoh K. Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients. <i>Drug Metab. Pharmacokinet.<\/i>, <b>28<\/b>, 132\u2013137 (2013).","DOI":"10.2133\/dmpk.DMPK-12-RG-078"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Hirai K, Yamada Y, Hayashi H, Tanaka M, Izumiya K, Suzuki M, Yoshizawa M, Moriwaki H, Akimoto T, Tsuji D, Inoue K, Itoh K. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy. <i>Thromb. Res.<\/i>, <b>135<\/b>, 861\u2013866 (2015).","DOI":"10.1016\/j.thromres.2015.02.019"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Bryk A, Wypasek E, Awsiuk M, Maj D, Undas A. Warfarin metabolites in patients following cardiac valve implantation: a contribution of clinical and genetic factors. <i>Cardiovasc. Drugs Ther.<\/i>, <b>29<\/b>, 257\u2013264 (2015).","DOI":"10.1007\/s10557-015-6591-8"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Hiratsuka M. Genetic polymorphisms and <i>in vitro<\/i> functional characterization of CYP2C8, CYP2C9, and CYP2C19 allelic variants. <i>Biol. Pharm. Bull.<\/i>, <b>39<\/b>, 1748\u20131759 (2016).","DOI":"10.1248\/bpb.b16-00605"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Tanaka T, Ihara M, Fukuma K, Yamamoto H, Washida K, Kimura S, Kada A, Miyata S, Miyata T, Nagatsuka K. Influence of renal impairment and genetic subtypes on warfarin control in Japanese patients. <i>Genes<\/i>, <b>12<\/b>, 1537 (2021).","DOI":"10.3390\/genes12101537"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Wang D, Yong L, Zhang Q, Chen H. Impact of CYP2C19 gene polymorphisms on warfarin dose requirement: a systematic review and meta-analysis. <i>Pharmacogenomics<\/i>, <b>23<\/b>, 903\u2013911 (2022).","DOI":"10.2217\/pgs-2022-0106"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Nishiba H, Nagamine A, Yashima H, Takahashi Y, Higuchi Y, Sekizaki N, Nakamura H, Araki T, Takama N, Koitabashi N, Nakajima T, Kaneko Y, Ohyama Y, Yokoyama T, Imai K, Kurabayashi M, Yamamoto K, Obayashi K. Effect of genetic factors on the interindividual variability of warfarin dosage requirements in Japanese patients after adjusting for renal function. <i>Pharmazie<\/i>, <b>79<\/b>, 173\u2013177 (2024).","DOI":"10.31083\/ph.2024.4546"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Johnson MA. Influence of vitamin K on anticoagulant therapy depends on vitamin K status and the source and chemical forms of vitamin K. <i>Nutr. Rev.<\/i>, <b>63<\/b>, 91\u201397 (2005).","DOI":"10.1111\/j.1753-4887.2005.tb00126.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Karlson B, Leijd B, Hellstr\u00f6m K. On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment. <i>Acta Med. Scand.<\/i>, <b>220<\/b>, 347\u2013350 (1986).","DOI":"10.1111\/j.0954-6820.1986.tb02776.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Cushman M, Booth SL, Possidente CJ, Davidson KW, Sadowski JA, Bovill EG. The association of vitamin K status with warfarin sensitivity at the onset of treatment. <i>Br. J. Haematol.<\/i>, <b>112<\/b>, 572\u2013577 (2001).","DOI":"10.1046\/j.1365-2141.2001.02635.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Schurgers LJ, Shearer MJ, Hamuly\u00e1k K, St\u00f6cklin E, Vermeer C. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. <i>Blood<\/i>, <b>104<\/b>, 2682\u20132689 (2004).","DOI":"10.1182\/blood-2004-04-1525"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. <i>Thromb. Haemost.<\/i>, <b>93<\/b>, 872\u2013875 (2005).","DOI":"10.1160\/TH04-12-0773"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. <i>Blood<\/i>, <b>109<\/b>, 2419\u20132423 (2007).","DOI":"10.1182\/blood-2006-09-049262"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ford SK, Misita CP, Shilliday BB, Malone RM, Moore CG, Moll S. Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios. <i>J. Thromb. Thrombolysis<\/i>, <b>24<\/b>, 23\u201327 (2007).","DOI":"10.1007\/s11239-007-0014-z"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Rombouts EK, Rosendaal FR, Van Der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. <i>J. Thromb. Haemost.<\/i>, <b>5<\/b>, 2043\u20132048 (2007).","DOI":"10.1111\/j.1538-7836.2007.02715.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Rombouts EK, Rosendaal FR, van der Meer FJM. Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy. <i>Br. J. Haematol.<\/i>, <b>149<\/b>, 598\u2013605 (2010).","DOI":"10.1111\/j.1365-2141.2010.08108.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Kim KH, Choi WS, Lee JH, Lee H, Yang DH, Chae SC. Relationship between dietary vitamin K intake and the stability of anticoagulation effect in patients taking long-term warfarin. <i>Thromb. Haemost.<\/i>, <b>104<\/b>, 755\u2013759 (2010).","DOI":"10.1160\/TH10-04-0257"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Gebuis EPA, Rosendaal FR, van Meegen E, van der Meer FJM. Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study. <i>Haematologica<\/i>, <b>96<\/b>, 583\u2013589 (2011).","DOI":"10.3324\/haematol.2010.035162"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Majeed H, Rodger M, Forgie M, Carrier M, Taljaard M, Scarvelis D, Gonsalves C, Rodriguez RA, Wells PS. Effect of 200 \u03bcG\/day of vitamin K1 on the variability of anticoagulation control in patients on warfarin: a randomized controlled trial. <i>Thromb. Res.<\/i>, <b>132<\/b>, 329\u2013335 (2013).","DOI":"10.1016\/j.thromres.2013.07.019"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Leblanc C, Presse N, Lalonde G, Dumas S, Ferland G. Higher vitamin K intake is associated with better INR control and a decreased need for INR tests in long-term warfarin therapy. <i>Thromb. Res.<\/i>, <b>134<\/b>, 210\u2013212 (2014).","DOI":"10.1016\/j.thromres.2014.04.024"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Putriana NA, Rusdiana T, Rostinawati T, Nurfuadah I. Validation of R\/S-warfarin analysis method in human blood plasma using HPLC with fluorescence detection and its application to patient samples. <i>J. Pharm. Bioallied Sci.<\/i>, <b>16<\/b>, 44\u201350 (2024).","DOI":"10.4103\/jpbs.jpbs_563_22"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Ohno I, Araki T, Kawano M, Nakamura T, Yamamoto K. Sensitive and simple determination of vitamin K1 in human plasma by ultra-performance liquid chromatography coupled with a fluorescence detector. <i>J. Liq. Chromatogr. Relat. Technol.<\/i>, <b>36<\/b>, 1068\u20131077 (2013).","DOI":"10.1080\/10826076.2012.685908"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Hartmann S, Biliouris K, Lesko LJ, Nowak-G\u00f6ttl U, Trame MN. Quantitative systems pharmacology model-based predictions of clinical endpoints to optimize warfarin and rivaroxaban anti-thrombosis therapy. <i>Front. Pharmacol.<\/i>, <b>11<\/b>, 1041 (2020).","DOI":"10.3389\/fphar.2020.01041"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Kampouraki E, Avery PJ, Biss T, Kamali F. Association between CYP4F2 genotype and circulating plasma vitamin K concentration in children on chronic warfarin therapy: possible long-term implications for bone development and vascular health. <i>Pediatr. Blood Cancer<\/i>, <b>64<\/b>, e26653 (2017).","DOI":"10.1002\/pbc.26653"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Park J-W, Kim K-A, Park J-Y. Effects of ketoconazole, a CYP4F2 inhibitor, and CYP4F2*3 genetic polymorphism on pharmacokinetics of vitamin K1. <i>J. Clin. Pharmacol.<\/i>, <b>59<\/b>, 1453\u20131461 (2019).","DOI":"10.1002\/jcph.1444"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Kim YE, Woo HI, On YK, Kim JS, Lee SY. High intra- and inter-individual variability of plasma vitamin K concentrations in patients with atrial fibrillation under warfarin therapy. <i>Eur. J. Clin. Nutr.<\/i>, <b>69<\/b>, 703\u2013706 (2015).","DOI":"10.1038\/ejcn.2015.41"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Kwolek S, Deming P. Warfarin hypersensitivity due to gluten-sensitive enteropathy: a case study. <i>Clin. Lab. Sci.<\/i>, <b>25<\/b>, 78\u201380 (2012).","DOI":"10.29074\/ascls.25.2.78"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Takada H, Hifumi T, Bunya N, Kiriu N, Kato H, Koido Y, Kuroda Y. Acquired absolute vitamin K deficiency in a patient undergoing warfarin therapy. <i>Am. J. Emerg. Med.<\/i>, <b>32<\/b>, 688.e1\u2013688.e2 (2014).","DOI":"10.1016\/j.ajem.2013.12.018"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Suhara Y, Kamao M, Tsugawa N, Okano T. Method for the determination of vitamin K homologues in human plasma using high-performance liquid chromatography-tandem mass spectrometry. <i>Anal. Chem.<\/i>, <b>77<\/b>, 757\u2013763 (2005).","DOI":"10.1021\/ac0489667"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Xue L, Singla RK, Qin Q, Ding Y, Liu L, Ding X, Qu W, Huang C, Shen Z, Shen B, Miao L. Exploring the complex relationship between vitamin K, gut microbiota, and warfarin variability in cardiac surgery patients. <i>Int. J. Surg.<\/i>, <b>109<\/b>, 3861\u20133871 (2023).","DOI":"10.1097\/JS9.0000000000000673"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Greer FR, Marshall SP, Severson RR, Smith DA, Shearer MJ, Pace DG, Joubert PH. A new mixed micellar preparation for oral vitamin K prophylaxis: randomised controlled comparison with an intramuscular formulation in breast fed infants. <i>Arch. Dis. Child.<\/i>, <b>79<\/b>, 300\u2013305 (1998).","DOI":"10.1136\/adc.79.4.300"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Morris DP, Soute BA, Vermeer C, Stafford DW. Characterization of the purified vitamin K-dependent gamma-glutamyl carboxylase. <i>J. Biol. Chem.<\/i>, <b>268<\/b>, 8735\u20138742 (1993).","DOI":"10.1016\/S0021-9258(18)52936-7"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Buitenhuis HC, Soute BA, Vermeer C. Comparison of the vitamins K1, K2 and K3 as cofactors for the hepatic vitamin K-dependent carboxylase. <i>Biochim. Biophys. Acta, Gen. Subj.<\/i>, <b>1034<\/b>, 170\u2013175 (1990).","DOI":"10.1016\/0304-4165(90)90072-5"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Groenen-van Dooren MMCL, Soute BAM, Jie KSG, Thijssen HHW, Vermeer C. The relative effects of phylloquinone and menaquinone-4 on the blood coagulation factor synthesis in vitamin K-deficient rats. <i>Biochem. Pharmacol.<\/i>, <b>46<\/b>, 433\u2013437 (1993).","DOI":"10.1016\/0006-2952(93)90519-3"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Spronk HMH, Soute BAM, Schurgers LJ, Thijssen HHW, De Mey JGR, Vermeer C. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. <i>J. Vasc. Res.<\/i>, <b>40<\/b>, 531\u2013537 (2003).","DOI":"10.1159\/000075344"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Kawano M, Araki T, Yashima H, Nakamura T, Yamamoto K. The reductive activity of human liver microsomes for vitamin K epoxides. <i>Indones. J. Pharm.<\/i>, <b>2<\/b>, 7\u201313 (2020).","DOI":"10.24198\/idjp.v2i1.25302"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Yamanashi Y, Takada T, Suzuki H. Associations between lifestyle-related diseases and transporters involved in intestinal absorption and biliary excretion of cholesterol. <i>Biol. Pharm. Bull.<\/i>, <b>41<\/b>, 1\u201310 (2018).","DOI":"10.1248\/bpb.b17-00690"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Ramotar K, Conly JM, Chubb H, Louie TJ. Production of menaquinones by intestinal anaerobes. <i>J. Infect. Dis.<\/i>, <b>150<\/b>, 213\u2013218 (1984).","DOI":"10.1093\/infdis\/150.2.213"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Sakano T, Nagaoka T, Morimoto A, Hirauchi K. Measurement of K vitamins in human and animal feces by high-performance liquid chromatography with fluorometric detection. <i>Chem. Pharm. Bull.<\/i>, <b>34<\/b>, 4322\u20134326 (1986).","DOI":"10.1248\/cpb.34.4322"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Rishavy MA, Hallgren KW, Wilson LA, Usubalieva A, Runge KW, Berkner KL. The vitamin K oxidoreductase is a multimer that efficiently reduces vitamin K epoxide to hydroquinone to allow vitamin K-dependent protein carboxylation. <i>J. Biol. Chem.<\/i>, <b>288<\/b>, 31556\u201331566 (2013).","DOI":"10.1074\/jbc.M113.497297"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/10\/49_b26-00395\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:21:58Z","timestamp":1792210918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/10\/49_b26-00395\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00395","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"article-number":"b26-00395"}}